北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (6): 1078-1082. doi: 10.19723/j.issn.1671-167X.2021.06.012
罗澜1,2,邢晓燕2,肖云抒3,陈珂彦2,朱冯赟智2,张学武2,李玉慧2,△()
LUO Lan1,2,XING Xiao-yan2,XIAO Yun-shu3,CHEN Ke-yan2,ZHU Feng-yun-zhi2,ZHANG Xue-wu2,LI Yu-hui2,△()
摘要:
目的:探讨抗合成酶综合征 (anti-synthetase syndrome, ASS)患者心脏受累的临床及免疫学特征。方法:回顾性分析2003年4月至2020年11月于北京大学人民医院风湿免疫科住院治疗的96例ASS患者资料,包括人口学资料、临床表现(皮疹、肌肉损害等)、合并症及实验室指标(肌酶、炎性标志物、免疫球蛋白、补体、淋巴细胞亚群、自身抗体等), 依据有无心脏受累进行分组比较。结果:ASS患者心脏受累的发生率为25.0% (24/96),心脏受累的患者主要表现为心肌肌钙蛋白升高(75.0%, 18/24)、心包积液(33.3%, 8/24)、左心室舒张功能减退(33.3%, 8/24)、瓣膜反流(33.3%, 8/24)。心脏受累组患者的发病年龄大于无心脏受累组[(54.58±10.58)岁 vs. (48.47±13.22)岁, P=0.043],关节炎的发生率低(37.5% vs. 61.1%, P=0.044)。心脏受累组患者合并急进性间质性肺炎的发生率高于无心脏受累组(54.2% vs. 30.6%, P=0.037)。实验室指标方面,ASS合并心脏受累组的C反应蛋白[13.55 (8.96, 38.35) mg/L vs. 4.60 (1.37, 17.40) mg/L, P=0.001]和乳酸脱氢酶[408.0 (255.0, 587.0) U/L vs. 259.5 (189.8, 393.8) U/L, P=0.007]水平均明显高于无心脏受累组。此外,心脏受累组出现抗Ro-52抗体阳性的患者比例明显高于无心脏受累组(91.7% vs. 69.4%, P=0.029),而合并危险因素、谷丙转氨酶、谷草转氨酶、肌酸激酶、动态红细胞沉降率、铁蛋白、免疫球蛋白G、补体C3、补体C4及T/B/NK淋巴细胞亚群等方面,两组差异无统计学意义。结论:ASS患者心脏受累常见,以心肌受损为主,合并C反应蛋白和乳酸脱氢酶升高、抗Ro-52抗体阳性的ASS患者应警惕心脏受累。
中图分类号:
[1] |
Jayakumar D, Zhang R, Wasserman A, et al. Cardiac manifestations in idiopathic inflammatory myopathies: An overview[J]. Cardiol Rev, 2019, 27(3):131-137.
doi: 10.1097/CRD.0000000000000241 pmid: 30585794 |
[2] |
Opinc AH, Makowski MA, Lukasik ZM, et al. Cardiovascular complications in patients with idiopathic inflammatory myopathies: Does heart matter in idiopathic inflammatory myopathies?[J]. Heart Fail Rev, 2021, 26(1):111-125.
doi: 10.1007/s10741-019-09909-8 |
[3] |
Sharma K, Orbai AM, Desai D, et al. Brief report: Antisynthetase syndrome-associated myocarditis[J]. J Card Fail, 2014, 20(12):939-945.
doi: 10.1016/j.cardfail.2014.07.012 |
[4] |
Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?[J]. Chest, 2010, 138(6):1464-1474.
doi: 10.1378/chest.10-0180 |
[5] |
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: An international collaborative tool to facilitate myositis research[J]. Ann Rheum Dis, 2018, 77(1):30-39.
doi: 10.1136/annrheumdis-2017-211868 pmid: 28855174 |
[6] | Li Y, Gao X, Li Y, et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7:363. |
[7] |
Dieval C, Deligny C, Meyer A, et al. Myocarditis in patients with antisynthetase syndrome: Prevalence, presentation, and outcomes[J]. Medicine (Baltimore), 2015, 94(26):e798.
doi: 10.1097/MD.0000000000000798 |
[8] | Katz A, Bena J, Chatterjee S. Antisynthetase syndrome: Prevalence of serositis in autoantibody subsets [C/OL]. 2018 ACR/ARHP Annual Meeting [2021-06-17]. https://acrabstracts.org/abstract/antisynthetase-syndrome-prevalence-of-serositis-in-autoan-tibody-subsets/. |
[9] | Ketlogetswe KS, Aoki J, Traill TA, et al. Severe aortic regurgitation secondary to antisynthetase syndrome[J]. Circulation, 2011, 124(3):e40-e41. |
[10] |
Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis[J]. Curr Rheumatol Rep, 2012, 14(3):275-285.
doi: 10.1007/s11926-012-0249-3 |
[11] |
Wang H, Liu T, Cai YY, et al. Pulmonary hypertension in polymyositis[J]. Clin Rheumatol, 2015, 34(12):2105-2112.
doi: 10.1007/s10067-015-3095-7 pmid: 26468158 |
[12] |
Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature[J]. Medicine (Baltimore), 2012, 91(4):206-211.
doi: 10.1097/MD.0b013e318260977c |
[13] |
Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012, 41(6):890-899.
doi: 10.1016/j.semarthrit.2011.09.008 |
[14] |
La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease[J]. Autoimmunity, 2006, 39(3):249-253.
pmid: 16769659 |
[15] |
Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020, 172(12):106134.
doi: 10.1016/j.rmed.2020.106134 |
[1] | 肖云抒,朱冯赟智,罗澜,邢晓燕,李玉慧,张学武,沈丹华. 88例重叠肌炎的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53(6): 1088-1093. |
[2] | 张朴丽,杨红霞,张立宁,葛勇鹏,彭清林,王国春,卢昕. 血清YKL-40在诊断抗黑色素瘤分化相关基因5阳性皮肌炎合并严重肺损伤中的价值[J]. 北京大学学报(医学版), 2021, 53(6): 1055-1060. |
[3] | 伊文霞,魏翠洁,吴晔,包新华,熊晖,常杏芝. 长疗程利妥昔单抗治疗难治性幼年型特发性炎症性肌病3例[J]. 北京大学学报(医学版), 2021, 53(6): 1191-1195. |
[4] | 吴燕芳,高飞,林滇恬,陈志涵,林禾. 托法替布联合治疗抗MDA5抗体阳性的无肌病皮肌炎并发快速进展型间质性肺病5例临床分析[J]. 北京大学学报(医学版), 2021, 53(5): 1012-1016. |
[5] | 郑艺明,郝洪军,刘怡琳,郭晶,赵亚雯,张巍,袁云. Ro52抗体与其他肌炎抗体共阳性的相关性研究[J]. 北京大学学报(医学版), 2020, 52(6): 1088-1092. |
[6] | 甘雨舟,李玉慧,张丽华,马琳,何文雯,金月波,安媛,栗占国,叶华. 临床无肌病性皮肌炎与皮肌炎临床及免疫学特征比较[J]. 北京大学学报(医学版), 2020, 52(6): 1001-1008. |
[7] | 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报(医学版), 2020, 52(6): 1009-1013. |
[8] | 朱冯赟智,邢晓燕,汤晓菲,李依敏,邵苗,张学武,李玉慧,孙晓麟,何菁. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52(6): 995-1000. |
[9] | 杨红霞,田小兰,江薇,李文丽,刘青艳,彭清林,王国春,卢昕. 免疫介导坏死性肌病的临床和病理特征分析[J]. 北京大学学报(医学版), 2019, 51(6): 989-995. |
[10] | 李英妮,相晓红,赵静,李云,孙峰,王红彦,贾汝琳,胡凡磊. 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报(医学版), 2019, 51(6): 1019-1024. |
[11] | 徐婧,徐静,李鹤,唐杰,舒建龙,张婧,石连杰,李胜光. 皮肌炎合并IgA血管炎1例[J]. 北京大学学报(医学版), 2019, 51(6): 1173-1177. |
[12] | 杨伊莹,左晓霞,朱红林,刘思佳. 皮肌炎/多肌炎表观遗传学标志物的研究进展[J]. 北京大学学报(医学版), 2019, 51(2): 374-377. |
[13] | 王永福,刘媛. 自身抗体在肿瘤及感染性疾病发生、发展中的作用[J]. 北京大学学报(医学版), 2018, 50(6): 952-955. |
[14] | 余建峰, 金月波, 何菁, 安媛, 栗占国. 皮肌炎继发干燥综合征伴肺间质病变的血清人Ⅱ型肺泡细胞表面抗原变化1例[J]. 北京大学学报(医学版), 2017, 49(5): 910-914. |
[15] | 刘洪江, 石连杰, 胡凡磊, 姚海红, 栗占国, 贾园. 趋化因子配体19在系统性红斑狼疮中的表达及其与B细胞异常的相关性研究[J]. 北京大学学报(医学版), 2017, 49(5): 829-834. |
|